The drug is administered subcutaneously ... investigating treatments for people living with hemophilia. In April, the FDA ...

Earlier this year, FDA approved Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...

Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...

The Food and Drug Administration on Friday approved a new kind of medicine for hemophilia, clearing Pfizer’s Hympavzi for people ... to receive Hympavzi, the FDA said. The drug is taken once ...

“Today’s approval of Hympavzi provides patients with hemophilia a new treatment ... The FDA granted Hympavzi Orphan Drug designation for this application. The FDA granted the approval of Hympavzi to ...

Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...